Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03199651 · ClinicalTrials.gov registry record · NA
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
A NA study of Stage IV Non-small Cell Lung Cancer and Lung Adenocarcinoma, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 3,584
- Enrollment target
- 1
- Study location
NCT03199651: Recruiting NA study of Stage IV Non-small Cell Lung Cancer and Lung Adenocarcinoma, sponsored by Ohio State University Comprehensive Cancer Center.
NCT03199651 is a NA study of Stage IV Non-small Cell Lung Cancer and Lung Adenocarcinoma that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 3,584 participants, above the 534-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (571% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03199651, a NA study of Stage IV Non-small Cell Lung Cancer and Lung Adenocarcinoma, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 3,584 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized clinical trial studies the Beating Lung Cancer in Ohio protocol in improving survival in patients with stage IV non-small cell lung cancer. The Beating Lung Cancer in Ohio protocol may help in evaluating immunotherapies and targeted therapies that prolong survival, have more favorable toxicity profiles than conventional chemotherapy and impact quality of life.
Primary Outcome
Using the payer perspective, Incremental Cost-Effectiveness Ratio (ICER) will be calculated based on estimates of overall survival/health care resource costs associated with treatment and the EQ5D questionnaire.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Laboratory Biomarker Analysis
- OTHER Medical Chart Review
- OTHER Best Practice
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,584 participants |
| Start Date | 2017-07-17 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What NCT03199651 shows while recruiting
NCT03199651 is an interventional study that assigns participants to a tested intervention. Its 3,584 participants enrollment target places it among the larger protocols in the corpus, above the 534-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (571% higher).
The record links to 5 conditions, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT03199651 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03199651 about?
NCT03199651 is a clinical study titled "Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer". This randomized clinical trial studies the Beating Lung Cancer in Ohio protocol in improving survival in patients with stage IV non-small cell lung cancer. The Beating Lung Cancer in Ohio protocol may help in evaluating immunotherapies and targeted therapies that prolong survival, have more favorabl...
What is the current status of trial NCT03199651?
This trial is currently recruiting. It is a NA study. The enrollment target is 3,584 participants. The study started on 2017-07-17. Estimated completion is 2028-12-31.
What conditions does trial NCT03199651 study?
This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer, Lung Adenocarcinoma, Cigarette Smoker, Current Smoker, Squamous Cell Lung Carcinoma.
What interventions are being tested in trial NCT03199651?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Medical Chart Review (OTHER), Best Practice (OTHER).
Who is sponsoring clinical trial NCT03199651?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03199651 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03199651's enrollment target sits among peer trials
3,584 2nd of 23 the highest of 23 other Stage IV Non-small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Non-small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient-centered, Optimal Integration of Survivorship and Palliative Care
RECRUITING · NA
-
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
RECRUITING · NA
-
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
COMPLETED · NA
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
ACTIVE NOT RECRUITING · Phase 1
-
Ruxolitinib for Cancer Cachexia
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06429787 · 3,574 participants
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
- NCT06088498 · 3,600 participants · Phase 2
App for Reducing Cravings to Smoke
- NCT06501118 · 3,600 participants · NA
Optimizing Care in Critically Ill at UCHealth by Liberalizing the Target O2 in Mechanically-ventilated ICU Patients
- NCT06919419 · 3,600 participants · NA
HOTSPOT Study: Implement and Evaluate the PrEP (Pre-exposure Prophylaxis) Implementation Strategy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI